US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous
Executive Summary
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
You may also be interested in...
Commissioner Hahn Self-Quarantines, But US FDA's Operations Will Likely Remain Unaffected
Since most employees already are teleworking, Stephen Hahn’s forced isolation due to potential coronavirus exposure should not cause many disruptions, former FDA officials say.
Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
White House Hypes Chloroquine, A Drug Currently In Shortage, As Coronavirus Treatment Hope
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.